Algernon Pharmaceuticals (Algernon Pharmaceuticals) Net Change in Cash : $-0.11 Mil (TTM As of Feb. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Algernon Pharmaceuticals's Net Change in Cash for the three months ended in Feb. 2024 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Feb. 2024 was $-0.11 Mil.

Algernon Pharmaceuticals Net Change in Cash Historical Data

The historical data trend for Algernon Pharmaceuticals's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Net Change in Cash Chart

Algernon Pharmaceuticals Annual Data

Trend

Aug15

Aug16

Aug17

Aug18

Aug19

Aug20

Aug21

Aug22

Aug23

Net Change in Cash

Get a 7-Day Free Trial

-0.79

4.47

-2.94

-0.78

-0.95

Algernon Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Net Change in Cash	Get a 7-Day Free Trial															-0.35	0.16	-0.23	-0.04	-

Algernon Pharmaceuticals Net Change in Cash Calculation

Algernon Pharmaceuticals's Net Change in Cash for the fiscal year that ended in Aug. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-1.894	+	-0.045	+	0.986	+	0
	=	-0.95

Algernon Pharmaceuticals's Net Change in Cash for the quarter that ended in Feb. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -0.177 + -0.017 + 0.197 + -0.001

= 0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Algernon Pharmaceuticals Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (OTCPK:AGNPF) » Definitions » Net Change in Cash

Comparable Companies

XCNQ:MOOD XCNQ:CURE XCNQ:GTTX TSXV:IBO TSXV:PSYB XCNQ:ENBI TSXV:VXL XCNQ:ABRT XCNQ:MYND TSXV:SVS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX

Traded in Other Exchanges

AGW0:Germany AGN:Canada

Address

601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2

Website

https://www.algernonpharmaceuticals.com

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Algernon Pharmaceuticals (Algernon Pharmaceuticals) Headlines

From GuruFocus

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
By Ds*** Ds*** • 09-01-2022

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD
By sperokesalga sperokesalga • 05-31-2023

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time
By sperokesalga sperokesalga • 04-20-2023

Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase
By sperokesalga sperokesalga • 02-16-2023

The Power Play by The Market Herald Releases New Interviews with Algernon, Permex Petroleum, Infinity Stone, Green River Gold, HIRE Technologies, and Aton Resources Discussing Their Latest News
By ACCESSWIRE ACCESSWIRE • 09-01-2022

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor
By sperokesalga sperokesalga • 02-21-2023

Algernon Pharmaceuticals Announces Launch of Rights Offering
By sperokesalga sperokesalga • 03-21-2023

Algernon Pharmaceuticals Announces Closing of Rights Offering
By sperokesalga sperokesalga • 05-05-2023

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH
By Marketwired • 09-06-2023

Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company's Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering
By Stock market mentor Stock market mentor • 01-03-2023